Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction

Clinical Cardiology

Volumn 31, Issue 12, 2008, Pages 572-579

  Jeong, Young Hoon ^a   Lee, Seung Whan ^b   Cheol, Whan Lee ^b   Hong, Myeong Ki ^b   Kim, Jae Joong ^b   Park, Seong Wook ^b   Park, Seung Jung ^b   Park, Duk Woo ^b   Kim, Young Hak ^b  

^a Gyeongsang National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Biomarker; Drug eluting stent; ST elevation myocardial infarction; Thrombolysis in myocardial infarction risk score

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PACLITAXEL; RAPAMYCIN; TROPONIN I;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; SCORING SYSTEM; ST ELEVATION MYOCARDIAL INFARCTION; ST SEGMENT ELEVATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; STENTS; TROPONIN I; YOUNG ADULT;

EID: 58149083996     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20403     Document Type: Article

References (21)

1. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639
2. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322
3. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-1969
4. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, et al.: Early prognostic usefulness of C-reactive protein added to the thrombolysis in myocardial infarction risk score in acute coronary syndromes. Am J Cardiol 2005;96:533-537
5. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, et al.: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91
6. Hoffmann R, Suliman H, Haager P, Christott P, Lepper W, et al.: Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 2006;186:177-183
7. Mega JL, Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, et al.: B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction; an ENTIRE-TIMI-23substudy. J Am Coll Cardiol 2004;44:335-339
8. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation 2002;105:1760-1763
9. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, et al.; A to Z Investigators: Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-2871
10. Niccoli G, Lanza GA, Spaziani C, Altamura L, Romagnoli E, et al.: Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007;117:306-311
11. Wilson RF, Laxson DD, Lesser JR, White CW: Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesion. Lancet 1989;1:807-811
12. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al.; Academic Research Consortium: Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351
13. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-281
14. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, et al.: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-1272
15. Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, et al.: Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000;21:1514-1521
16. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, et al.: Plasma N-terminal pre-brain natriretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-1929
17. Grabowski M, Filipiak KJ, Karpinski G, Wretowski D, Rdzanek A, et al.: Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J 2004;148:655-662
18. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.; TYPHOON Investigators: Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-1104
19. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113
20. Robinson CR, Martin JL, Zhang L, Canham RM, Abdullah SM, et al.: Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction. Am J Cardiol 2006;97:7-9
21. Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, et al.: Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. The GUSTO III Investigators Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999;84:1281-1286